首页|纳米递送技术用于幽门螺杆菌疫苗研发的进展

纳米递送技术用于幽门螺杆菌疫苗研发的进展

扫码查看
幽门螺杆菌感染与一系列胃肠道疾病的发生息息相关,而目前用于抗幽门螺杆菌治疗的抗生素耐药性极大增加了感染复发率,导致其根治困难.疫苗是防治感染性疾病最有效的策略之一,然而,至今仍未有幽门螺杆菌疫苗上市.运用纳米技术提高疫苗稳定性和有效性已在实验室研究中初见成效,因此,本文对幽门螺杆菌疫苗的研发现状进行了总结,并归纳和讨论了幽门螺杆菌疫苗纳米递送系统的研究进展,包括黏液惰性纳米粒、耐酸性纳米粒、纳米囊泡等,以期为后续开发有效、安全的幽门螺杆菌疫苗提供参考.
Research progress of nano-delivery technology for the development of vaccines against Helicobacter pylori
Helicobacter pylori(H.pylori)infection is closely related to the occurrence of a series of gastrointestinal diseases.Antibiotic resistance in the current H.pylori treatment has greatly increased the recurrence rate of the infection,making its eradication difficult.Vaccine is one of the most effective strategies to prevent and control bacterial infectious diseases,however,there is still no anti-H.pylori vaccine on the market.The use of nanotechnology to improve vaccine stability and efficacy has shown promising results in laboratory studies.This paper summarizes the current status of anti-H.pylori vaccine development,and reviews and discusses the research progress of H.pylori vaccine based on nano-delivery systems,including mucus-inert nanoparticles,acid-resistant nanoparticles,and outer-membrane vesicles etc.,with the aim of providing a reference for the subsequent development of an effective and safe H.pylori vaccine.

Helicobacter pyloriCandidate antigenVaccineNanotechnology

宋紫娟、张远冬

展开 >

563000,遵义医科大学药学院

563000,遵义医科大学第一临床学院

幽门螺杆菌 候选抗原 疫苗 纳米技术

国家自然科学基金国家自然科学基金贵州省卫生健康委科研基金大学生创新训练项目

8216067882003686gzwkj2020-1-213ZYDC202302032

2024

免疫学杂志
第三军医大学,中国免疫学会

免疫学杂志

CSTPCD
影响因子:0.704
ISSN:1000-8861
年,卷(期):2024.40(4)